Targeted Therapy: Can It Substitute for Chemotherapy?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The goal in oncology is to maximize treatment efficacy while minimizing toxicity.
• Targeted therapies are crucial for identifying patient subgroups who benefit most from specific treatments.
• Targeted therapies have become integral to managing both primary and metastatic breast cancer.

Purpose of the Study:

• To review current targeted therapies used in clinical decisions for primary and metastatic breast cancer.
• To highlight the role of specific agents like trastuzumab and bevacizumab.
• To provide an overview of emerging targeted agents and strategies.

Main Methods:

• Review of established and investigational targeted therapies in breast cancer treatment.
• Focus on agents targeting specific molecular pathways, such as HER2/neu and vascular endothelial growth factor.
• Discussion of clinical relevance and future directions in targeted therapy research.

Main Results:

• Trastuzumab, a humanized monoclonal antibody, is effective in HER2/neu-overexpressing breast tumors.
• Bevacizumab targets vascular endothelial growth factor ligand A, inhibiting angiogenesis, with no known predictive factors.
• Investigational agents include tyrosine kinase inhibitors and other small molecules.

Conclusions:

• Targeted therapies are essential for personalized breast cancer treatment, improving outcomes by targeting specific tumor characteristics.
• Trastuzumab demonstrates significant efficacy in HER2-positive breast cancer.
• Ongoing research into novel targeted agents and strategies promises further advancements in reducing treatment toxicity and improving patient care.